Journal
FUTURE MEDICINAL CHEMISTRY
Volume 11, Issue 14, Pages 1741-1756Publisher
Newlands Press Ltd
DOI: 10.4155/fmc-2018-0274
Keywords
anticancer drug; apoptosis; carbosilane dendrimer; HL-60 cell line; necroptosis; ruthenium
Categories
Funding
- Marie Curie International Research Staff Exchange Scheme Fellowship within the 7th European Community Framework Programme [PIRSES-GA-2012-316730 NANOGENE]
- Horizon 2020 twinning on DNA-based cancer vaccines project [H2020-TWINN-2015/CSA-692293 VACTRAIN]
- Project EUROPARTNER of Polish National Agency for Academic Exchange (NAWA)
- Pl-SK 2019-2020 bilateral project of NAWA [PPN/BIL/2018/1/00150]
- 'NanoTENDO' project - M-ERA.NET-Call-2018 programme
Ask authors/readers for more resources
Coordination of ruthenium arene fragments on carbosilane dendrimers' surface greatly increases their antitumor properties. Newly synthetized ruthenium dendrimers are water-soluble, monodisperse and stable. Since carbosilane dendrimers are good carriers of drugs and genes, the presence of ruthenium in their structure makes them promising candidates for new drug delivery systems with improved antitumor potential. Carbosilane ruthenium dendrimers are more toxic to cancer cells than normal cells. Results of several in vitro studies applied here indicate that carbosilane ruthenium dendrimers induce apoptosis in promyelocytic leukemia HL-60 cells. [GRAPHICS] .
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available